November 2013 | OncologyLive

PI3K-Targeting Agents May Help Overcome Resistance in Breast Cancer Treatment

December 20, 2013

Through a variety of research roles, Sara Hurvitz, MD, is exploring novel targeted therapies for the treatment of breast cancer, including developing and implementing clinical trials. Her interests include the phosphatidylinositol 3-kinase (PI3K) signaling pathway.

FALCON Trial Compares Two Types of Endocrine Therapy

December 19, 2013

The question of whether fulvestrant (Faslodex) should be moved forward in the treatment timeline for postmenopausal women with advanced, hormone receptor (HR)-positive breast cancer is being evaluated in an international, randomized phase III trial.

Initiative Aims to Boost Clinical Trial Participation Among Asian-Americans

December 16, 2013

The UC Davis Comprehensive Cancer Center and the National Cancer Institute (NCI)-funded National Center for Reducing Asian American Cancer Health Disparities are working to address these disparities through programs to boost participation in clinical trials, collect biospecimens, and conduct blood genomics research.

Hematologic Immunotherapy Breaks New Ground in Established Field

December 06, 2013

Although immunotherapy advances in solid tumors have captured much attention in recent years, therapeutic strategies that enable the patient's own immune system to battle cancer cells have long been integrated into the treatment of patients with hematologic malignancies.

Mammogram Study Provides Rationale for Expanding Screening Programs

December 05, 2013

Most deaths from breast cancer occur in women who have not been regularly screened and whose tumors are diagnosed at a median age 49 years, confirming the need for the greater use of annual mammography in younger women, according to a recent study that marks the latest episode in the debate over screening guidelines.

Targeting PI3K: A New Generation of Agents Emerges

December 05, 2013

The phosphatidylinositol 3-kinase pathway is frequently deregulated in cancer at multiple different points, and has therefore emerged as one of the most deeply explored cell-signaling networks in oncogenic research.

RCC Care Evolving With Targeted and Novel Agents

December 04, 2013

With seven targeted therapies approved for metastatic renal cell carcinoma, researchers and drug developers are now focusing on understanding the best way to sequence these therapies and on identifying predictive biomarkers of response.

Beyond Tissue Biopsies: Blood Assays May Provide "Liquid" Molecular Analyses for "Solid" Tumors

November 27, 2013

While a number of biological and clinical factors differentiate so-called "solid" from "liquid" cancers, there is perhaps no single difference that is more relevant than the ability in liquid cancers to easily obtain malignant cells from the blood for subsequent analysis in the laboratory.

Swallowing Exercises Help to Preserve Function After RT and CRT

November 21, 2013

Head and neck cancer patients who participated in a swallow preservation protocol were less likely to suffer from the detrimental effects associated with dysphagia, a common complication associated with radiation therapy and chemoradiation therapy.